Kiora Pharmaceuticals (KPRX) and Its Rivals Head-To-Head Analysis

Kiora Pharmaceuticals (NASDAQ:KPRX) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Kiora Pharmaceuticals to similar businesses based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, risk and valuation.

Risk & Volatility

Kiora Pharmaceuticals has a beta of -0.13, indicating that its stock price is 113% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals’ peers have a beta of -3.80, indicating that their average stock price is 480% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Kiora Pharmaceuticals and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1	0	0	0	1.00
Kiora Pharmaceuticals Competitors	7803	13893	25800	1039	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.19%. Given Kiora Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals has less favorable growth aspects than its peers.

Profitability

This table compares Kiora Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Kiora Pharmaceuticals Competitors	-2,381.34%	-218.59%	-15.77%

Earnings and Valuation

This table compares Kiora Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02 million	-$10.84 million	-0.56
Kiora Pharmaceuticals Competitors	$3.54 billion	$3.16 billion	552.63

Kiora Pharmaceuticals’ peers have higher revenue and earnings than Kiora Pharmaceuticals. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kiora Pharmaceuticals peers beat Kiora Pharmaceuticals on 9 of the 13 factors compared.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.